Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;33 Suppl 27(Suppl 27):8-10.
doi: 10.1111/pai.13617.

New opportunities with biologic treatments in pediatric allergic and respiratory diseases

Laura Tenero  1 , Giorgio Piacentini  1
Affiliations

New opportunities with biologic treatments in pediatric allergic and respiratory diseases

Laura Tenero et al. Pediatr Allergy Immunol. 2022 Jan.

Abstract

In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics have also changed the management of these diseases in the pediatric population, tending toward personalized medicine based on the type-2 inflammatory pattern.

Keywords: asthma; atopic dermatitis; biologic agents; children; chronic urticaria.

PubMed Disclaimer

Conflict of interest statement

Authors declared they have no conflict of interests.

References

    1. Votto M, De Filippo M, Licari A, et al. Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review. Biologics. 2021;15:133‐142. - PMC - PubMed
    1. Tenero L, Arturi E, Piazza M, et al. Anti‐IL‐5 in pediatric allergic diseases. Pediatr Allergy Immunol. 2020;31(Suppl 26):14‐16. - PubMed
    1. Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatr Drugs. 2020;22:295‐310. - PubMed
    1. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1058‐1068. - PubMed
    1. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite using medium‐to‐high‐dose inhaled corticosteroids plus a long‐acting β2 agonist: a randomised double‐blind placebo‐controlled pivotal phase 2b dose‐ranging trial. Lancet. 2016;388:31‐44. - PubMed

Substances